NDA 202763 · Ani Pharms
Testosterone
Testosterone · Transdermal
DiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 25, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Feb 14, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
728
173 Phase 3, 64 recruiting
FAERS reports
19,071
10,928 serious, 779 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 14, 2012 Original approval · Type 3 - New Dosage Form ReviewMedication GuideSummary Review
2 products under this application
- TESTOSTERONE · TESTOSTERONE 25MG/2.5GM PACKET · GEL, TRANSDERMAL · Discontinued
- TESTOSTERONE · TESTOSTERONE 50MG/5GM PACKET · GEL, TRANSDERMAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Testosterone" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal MenPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03518034 · 5,246 participants · Start May 3, 2018 · Primary completion Jan 19, 2023
Drug: AndroGel®; Placebo · For: Hypogonadism; Cardiovascular Diseases
Sites: Alabaster, Alabama; Birmingham, Alabama; Decatur, Alabama · 384 sites in all
- Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal WomenPivotal-lookingCompleted
BioSante PharmaceuticalsIndustry
NCT00612742 · 3,656 participants · Start Jan 2008 · Primary completion Oct 2012
Drug: testosterone gel; placebo gel · For: Hypoactive Sexual Desire Disorder
Sites: Birmingham, Alabama; Hoover, Alabama; Huntsville, Alabama · 149 sites in all
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03767244 · 2,517 participants · Start Jun 11, 2019 · Primary completion Dec 1, 2026
Drug: Apalutamide; Androgen Deprivation Therapy (ADT) and 1 more · For: Prostatic Neoplasms
Sites: La Jolla, California; Los Angeles, California; Orange, California · 203 sites in all
- Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate CancerPivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01193244 · 1,560 participants · Start Oct 1, 2010 · Primary completion Jan 1, 2014
Drug: Orteronel; Placebo and 1 more · For: Prostate Cancer
Sites: Anchorage, Alaska; Tucson, Arizona; Duarte, California · 240 sites in all
- Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal WomenPivotal-lookingCompleted
Warner ChilcottIndustry
NCT00467259 · 1,271 participants · Start Apr 2007 · Primary completion Jan 2009
Drug: Testosterone Transdermal System; Placebo patch · For: Hypoactive Sexual Desire Disorder
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 115 sites in all
- Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot FlushesPivotal-lookingCompleted
Solvay PharmaceuticalsIndustry
NCT00160342 · 1,251 participants (planned) · Start Jun 2005 · Primary completion Sep 2007
Drug: Esterified Estrogens (EE) and Methyltestosterone (MT); Esterified Estrogens (EE) and Methyltestosterone (MT) and 7 more · For: Hot Flushes, Menopause, Postmenopause
Sites: Montgomery, Alabama; Tucson, Arizona; Jonesboro, Arkansas · 125 sites in all
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
- Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04623385 · 1,000 participants (planned) · Start Nov 2020 · Primary completion Dec 2020
Drug: The standard therapy · For: Covid19
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,467
- off label use1,232
- fatigue1,182
- nausea858
- headache776
- pain776
- diarrhoea628
- anxiety611
- asthenia598
- arthralgia595
- dizziness593
- dyspnoea549
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 169 |
| 2005 | 126 |
| 2006 | 139 |
| 2007 | 156 |
| 2008 | 188 |
| 2009 | 248 |
| 2010 | 307 |
| 2011 | 334 |
| 2012 | 875 |
| 2013 | 367 |
| 2014 | 556 |
| 2015 | 1,102 |
| 2016 | 1,059 |
| 2017 | 977 |
| 2018 | 1,138 |
| 2019 | 1,225 |
| 2020 | 1,198 |
| 2021 | 1,206 |
| 2022 | 1,419 |
| 2023 | 1,550 |
| 2024 | 1,640 |
| 2025 | 1,721 |
| 2026 | 1,371 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Testosterone (Testosterone)
2024 spending
$93.4M
Beneficiaries
132,638
556,670 claims
Per beneficiary
$704
$1.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $137,780,191 |
| 2021 | $124,155,588 |
| 2022 | $116,014,874 |
| 2023 | $116,855,572 |
| 2024 | $93,434,856 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers.
Pandit S, Biswas S, Jana U, et al. · Andrologia 2016 · Randomized Controlled Trial
- Testosterone dose-response relationships in healthy young men.
Bhasin S, Woodhouse L, Casaburi R, et al. · Am J Physiol Endocrinol Metab 2001 · Clinical Trial, Randomized Controlled Trial
- High-protein diets and testosterone.
Whittaker J · Nutr Health 2023 · Systematic Review, Meta-Analysis
- Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data.
Islam RM, Bell RJ, Green S, et al. · Lancet Diabetes Endocrinol 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Low-carbohydrate diets and men's cortisol and testosterone: Systematic review and meta-analysis.
Whittaker J, Harris M · Nutr Health 2022 · Meta-Analysis, Systematic Review
- Low-fat diets and testosterone in men: Systematic review and meta-analysis of intervention studies.
Whittaker J, Wu K · J Steroid Biochem Mol Biol 2021 · Meta-Analysis, Systematic Review
Sponsor: Ani Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.